Carregant...
Sorafenib for the treatment of hepatocellular carcinoma
The multikinase inhibitor sorafenib, which inhibits targets related to tumor cell proliferation and angiogenesis, was the first systemic agent to demonstrate a significant improvement in the overall survival for patients with advanced hepatocellular carcinoma (HCC) in two large randomized controlled...
Guardat en:
| Publicat a: | Hepat Oncol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Future Medicine Ltd
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6095169/ https://ncbi.nlm.nih.gov/pubmed/30190954 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep.13.20 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|